Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia

Mohana et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.031 (date from preprint)
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Safety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and has minimal side effects. No ICU admission or deaths were reported.
Mohana et al., 17 Oct 2020, peer-reviewed, 15 authors.
This PaperHCQAll
Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia
Abdulrhman Mohana, Tarek Sulaiman, Nagla Mahmoud, Mustafa Hassanein, Amel Alfaifi, Eissa Alenazi, Nashwa Radwan, Nasser Alkhalifah, Ehab Elkady, Abdullah Almohaizeie, Fouad Abogazalah, Khaled Alabdulkareem, Fahad Alghofaili, Hani Jokdar, Fahad Alrabiah
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.031
Background: Global health has been challenged by the COVID-19 pandemic since late 2019. Multiple approaches have been applied to relieve pressure on and support existing healthcare. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the national healthcare system. Since 5 June 2020, 238 outpatient fever clinics have been established nationwide. This study aimed to assess the safety outcome and reported adverse events from hydroxychloroquine use among suspected COVID-19 patients. Methods: The cross-sectional study included 2733 patients subjected to the MOH treatment protocol (hydroxychloroquine) and followed up for 3-7 days after initiation. Data were collected through an electronic link and cross-checked with the national database (Health Electronic Surveillance Network) and reports from the MOH Morbidity and Mortality Committee. Results: Two hundred and forty patients (8.8%) discontinued treatment because of side effects (4.1%) and non-clinical reasons (4.7%). Adverse effects were reported among 6.7% of all participants, including mainly cardiovascular symptoms (2.5%; 0.15% with corrected QT prolongation) and gastrointestinal symptoms (2.4%). No intensive care unit admission or death was reported among these patients. Conclusion: Our results show that hydroxychloroquine use for COVID-19 patients with mild to moderate symptoms in an outpatient setting with the recommended protocol and inclusion/exclusion criteria is safe, is highly tolerable and has minimal side effects.
Conflict of interest None declared. Ethics approvals This research was approved and followed closely by the Ministry of Health Institutional Review Board (log number 20-129M). Informed consent was obtained, by the treating physician, from the participants after explanation of the study. Those who refused to participate in the study were excluded and continued with standard supportive care. All information collected was kept confidential and will not be used for purposes other than the study.
References
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19, N Engl J Med, doi:10.1056/NEJMoa2019014
Eljaalya, Alirezaa, Alshehria, Tawfiqc, Hydroxychloroquine safety: a meta-analysis of randomised controlled trials, Travel Med Inf Dis, doi:10.1016/j.tmaid.2020.101812
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomised clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalised patients with Covid-19, N Engl J Med
Hooks, Bart, Vardeny, Westanmo, Adabag, Effects of hydroxychloroquine treatment on QT interval, Heart Rhythm, doi:10.1016/j.hrthm.2020.06.029
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101791
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARSCoV-2 infection in vitro, Cell Discov
Lofgren, Nicol, Bangdiwala, Pastick, Okafor et al., Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19, medRxiv, doi:10.1101/2020.07.16.20155531
Rosenberg, Dufort, Udo, Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Satlini, Goyal, Magleby, Maldarelli, Pham et al., Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalised patients with coronavirus 2019 disease, PLoS One, doi:10.1371/journal.pone.0236778
Skipper, Pastick, Engen, Bangdiwala, Abassi et al., Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial, Ann Intern Med, doi:10.7326/M20-4207
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ, doi:10.1136/bmj.m1849
Wu, Wu, Liu, The SARS-CoV-2 outbreak: what we know, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.004
{ 'indexed': {'date-parts': [[2024, 5, 1]], 'date-time': '2024-05-01T00:43:55Z', 'timestamp': 1714524235370}, 'reference-count': 15, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2020, 10, 12]], 'date-time': '2020-10-12T00:00:00Z', 'timestamp': 1602460800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': { 'domain': [ 'ijidonline.com', 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.fr', 'clinicalkey.com.au', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 1]]}, 'DOI': '10.1016/j.ijid.2020.10.031', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 10, 17]], 'date-time': '2020-10-17T01:21:48Z', 'timestamp': 1602897708000}, 'page': '110-114', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 5, 'title': 'Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients ' 'in Saudi Arabia', 'prefix': '10.1016', 'volume': '102', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-9646-5635', 'authenticated-orcid': False, 'given': 'Abdulrhman', 'family': 'Mohana', 'sequence': 'first', 'affiliation': []}, {'given': 'Tarek', 'family': 'Sulaiman', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3801-1974', 'authenticated-orcid': False, 'given': 'Nagla', 'family': 'Mahmoud', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8523-9592', 'authenticated-orcid': False, 'given': 'Mustafa', 'family': 'Hassanein', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amel', 'family': 'Alfaifi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eissa', 'family': 'Alenazi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nashwa', 'family': 'Radwan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nasser', 'family': 'AlKhalifah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ehab', 'family': 'Elkady', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-4920-3741', 'authenticated-orcid': False, 'given': 'Abdullah', 'family': 'Almohaizeie', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fouad', 'family': 'AboGazalah', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-1865-178X', 'authenticated-orcid': False, 'given': 'Khaled', 'family': 'AlabdulKareem', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fahad', 'family': 'AlGhofaili', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hani', 'family': 'Jokdar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fahad', 'family': 'Alrabiah', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijid.2020.10.031_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '44', 'DOI': '10.1016/j.ijid.2020.03.004', 'article-title': 'The SARS-CoV-2 outbreak: What we know', 'volume': '94', 'author': 'Wu', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0010', 'series-title': 'Clinical management of severe acute respiratory infection (SARI) when ' 'COVID-19 disease is suspected: interim guidance. ' 'WHO/2019-nCoV/clinical/2020.4. the 13th of March', 'author': 'World Health Organization (WHO)', 'year': '2020'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0015', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting SARSCoV-2 infection in vitro', 'volume': '6', 'author': 'Liu', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0020', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomised clinical trial', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '2411', 'DOI': '10.1056/NEJMoa2012410', 'article-title': 'Observational study of hydroxychloroquine in hospitalised patients with ' 'Covid-19', 'volume': '382', 'author': 'Geleris', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0030', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jama.2020.8630', 'article-title': 'association of treatment with hydroxychloroquine or azithromycin with ' 'in-hospital mortality in patients with COVID-19 in New York State', 'volume': '323', 'author': 'Rosenberg', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0035', 'unstructured': 'Saudi Ministry of Health Protocol for patients suspected/confirmed with ' 'COVID-19. ' 'https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf ' '2020 Version 1.6 May 24th.'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0040', 'series-title': 'Effects of hydroxychloroquine treatment on QT interval. 1547-5271/$-see ' 'front matter Published by Elsevier Inc. on behalf of Heart Rhythm ' 'Society', 'author': 'Hooks', 'year': '2020'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0045', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2019014', 'article-title': 'Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate ' 'Covid-19', 'author': 'Cavalcanti', 'year': '2020', 'journal-title': 'NEJM the 23rd of July'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0050', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101791', 'article-title': 'Outcomes of 3,737 COVID-19 patients treated with ' 'hydroxychloroquine/azithromycin and other regimens in Marseille, ' 'France: a retrospective analysis', 'author': 'Lagier', 'year': '2020', 'journal-title': 'Travel Medicine and Infectious Disease'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0055', 'doi-asserted-by': 'crossref', 'first-page': 'm1849', 'DOI': '10.1136/bmj.m1849', 'article-title': 'Hydroxychloroquine in patients with mainly mild to moderate coronavirus ' 'disease 2019: open label, randomised controlled trial', 'volume': '369', 'author': 'Tang', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0060', 'article-title': 'Safety of Hydroxychloroquine among Outpatient Clinical Trial ' 'Participants for COVID-19', 'author': 'Lofgren', 'year': '2020', 'journal-title': 'medRxiv preprint the 23rd of July'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0065', 'unstructured': 'SatlinI MJ, Goyal P, Magleby R, Maldarelli GA, Pham K, KondoI M et al. ' 'Safety, tolerability, and clinical outcomes of hydroxychloroquine for ' 'hospitalised patients with coronavirus 2019 disease PLoS ONE 15(7): ' 'e0236778.https://doi.org/10.1371/journal. pone.0236778h.'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0070', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101812', 'article-title': 'Hydroxychloroquine safety: A meta-analysis of randomised controlled ' 'trials', 'author': 'Eljaalya', 'year': '2020', 'journal-title': 'Travel Medicine and Infectious Disease.'}, { 'key': '10.1016/j.ijid.2020.10.031_bib0075', 'first-page': 'M20', 'article-title': 'Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A ' 'Randomized Trial', 'author': 'Skipper', 'year': '2020', 'journal-title': 'Ann Intern Med.'}], 'container-title': 'International Journal of Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971220322359?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971220322359?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 4, 21]], 'date-time': '2021-04-21T21:25:07Z', 'timestamp': 1619040307000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1201971220322359'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1]]}, 'references-count': 15, 'alternative-id': ['S1201971220322359'], 'URL': 'http://dx.doi.org/10.1016/j.ijid.2020.10.031', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.1101/2020.08.16.20175752', 'asserted-by': 'object'}]}, 'ISSN': ['1201-9712'], 'subject': [], 'container-title-short': 'International Journal of Infectious Diseases', 'published': {'date-parts': [[2021, 1]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for ' 'COVID-19 Outpatients in Saudi Arabia', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Infectious Diseases', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijid.2020.10.031', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 The Author(s). Published by Elsevier Ltd on behalf of International ' 'Society for Infectious Diseases.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit